Skip to main content
In case of a medical emergency, please contact your local HCP for further assistance.

Drug Safety Reporting

At Cipla we take the safety of our patients and consumers very seriously. We know that side effects can happen but it is not always possible to predict who will get them. For this reason, it is vital for us to continuously monitor the safety of our products. By hearing about your experiences and others like you we are able to offer the best possible advice to those using Cipla’s products.

Contact Drug Safety

Tel: 080 222 6662
Email: drugsafetysa@cipla.com

Important Medicine Safety Information

Valaciclovir/Aciclovir - Containing Medicines – Risk Of Drug Reaction With Eosinophilia And Systemic Symptoms (Dress)
DHCPL – IV Tranexamic Acid Risk of Intrathecal Administration Error
DHCPL for Pseudoephedrine-containing Medicines
DHCPL for Genotoxic Anticancer Medicines
Gabapentinoids Risk of Serious Breathing Difficulty
Selective Serotonin Reuptake Inhibitors (SSRIs) And Serotonin– Norepinephrine Reuptake Inhibitors (SNRIs)
Proton Pump Inhibitors
Fluoropyrimidine Containing Medicines and related substances
Tyrosine Kinase Inhibitor containing medicines
Ondansetron
Fluoroquinolones

Lenalidomide

Lenalidomide Checklist for Counselling
Lenalidomide HCP Information brochure
Lenalidomide Patient Information Brochure
Pharmacy Registration Form
Prescriber Registration Form
Prescription Authorisation Form
Treatment Initiation Form
Pregnancy Report Form

Abacavir | Lamivudine | Lopinavir | Ritonavir (Quadrimune)

Patient Alert Card

Dolutegravir | Lamivudine | Tenofovir disoproxil fumarate

Adverse Event Report Form
Renal Risk Minimisation Material: Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B
Renal And Bone Effects Risk Minimisation Material: Tenofovir Disoproxil For Children And Adolescents With Hiv-1

Related Links

Office Locations
Product Complaints and Information
Cipla Foundation Contacts
For Media
Contact Us